Jiang Yanjun, Fang Zhengfeng, Guthrie Gregory, Stoll Barbara, Chacko Shaji, Lin Sen, Hartmann Bolette, Holst Jens J, Dawson Harry, Pastor Jose J, Ipharraguerre Ignacio R, Burrin Douglas G
USDA/ARS Children's Nutrition Research Center, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor College of Medicine, Houston, Texas USA.
Key Laboratory of Agricultural Product Processing and Nutrition Health (Co-construction by Ministry and Province), Ministry of Agriculture and Rural Affairs, College of Food Science, Sichuan Agricultural University, Ya'an, China.
bioRxiv. 2024 Sep 7:2024.09.03.611073. doi: 10.1101/2024.09.03.611073.
BACKGROUND & AIMS: We aimed to investigate the relative efficacy of feeding different bile acids in preventing PNALD in neonatal pigs.
Newborn pigs given total parenteral nutrition (TPN) combined with minimal enteral feeding of chenodeoxycholic acid (CDCA), or increasing doses of obeticholic acid (OCA) for 19 days.
Enteral OCA (5 and 15 mg/kg), but not CDCA (30 mg/kg) reduced blood cholestasis markers compared to TPN controls and increased bile acids in the gallbladder and intestine. Major bile acids in the liver and distal intestine were CDCA, HCA, HDCA and OCA, and their relative proportions were increased by the type of bile acid (CDCA or OCA) given enterally. High doses of OCA increased the total NR1H4-agonistic bile acid profile in the liver and intestine above 50% total bile acids. Both CDCA and OCA treatments suppressed hepatic cyp7a1 expression, but only OCA increased hepatobiliary transporters, ABCB11, ABCC$ and ABCB1. Plasma phytosterol levels were reduced and biliary levels were increased by CDCA and OCA and hepatic sterol transporters, abcg5/8, expression were increased by OCA. Both CDCA and OCA increased plasma FGF19 and OCA increased intestinal FGF19, FABP6, and SLC51A. Both CDCA and OCA increased intestinal mucosal growth, whereas CDCA increased the plasma GLP-2, GLP-1 and GIP.
Enteral OCA prevented cholestasis and phytosterolemia by increased hepatic bile acid and sterol transport via induction of hepatobiliary transporter FXR target genes and not by suppression of bile acid synthesis genes. We also showed an intestinal trophic action of OCA that demonstrates a dual clinical benefit of FXR agonism in the prevention of PNALD in piglets.
我们旨在研究喂养不同胆汁酸对预防新生仔猪发生PNALD的相对疗效。
给新生仔猪进行全胃肠外营养(TPN),并联合微量肠内喂养鹅去氧胆酸(CDCA),或给予递增剂量的奥贝胆酸(OCA),持续19天。
与TPN对照组相比,肠内给予OCA(5毫克/千克和15毫克/千克)而非CDCA(30毫克/千克)可降低血液胆汁淤积标志物,并增加胆囊和肠道中的胆汁酸。肝脏和远端肠道中的主要胆汁酸为CDCA、HCA、HDCA和OCA,其相对比例因肠内给予的胆汁酸类型(CDCA或OCA)而增加。高剂量的OCA使肝脏和肠道中总NR1H4激动性胆汁酸谱增加至总胆汁酸的50%以上。CDCA和OCA治疗均抑制肝脏cyp7a1表达,但只有OCA增加肝胆转运蛋白ABCB11、ABCC$和ABCB1。CDCA和OCA可降低血浆植物甾醇水平,增加胆汁中植物甾醇水平,OCA可增加肝脏甾醇转运蛋白abcg5/8的表达。CDCA和OCA均增加血浆FGF19,OCA增加肠道FGF19、FABP6和SLC51A。CDCA和OCA均增加肠道黏膜生长,而CDCA增加血浆GLP-2、GLP-1和GIP。
肠内给予OCA可通过诱导肝胆转运蛋白FXR靶基因增加肝脏胆汁酸和甾醇转运,从而预防胆汁淤积和植物甾醇血症,而非通过抑制胆汁酸合成基因。我们还显示了OCA的肠道营养作用,这证明了FXR激动剂在预防仔猪PNALD方面具有双重临床益处。